Department of Internal Medicine, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC H3A 1G1, Canada.
Department of Anatomy & Cell Biology, McGill University, Montreal, QC H3A 1G1, Canada.
Curr Oncol. 2024 Oct 18;31(10):6314-6342. doi: 10.3390/curroncol31100471.
Antibody-drug conjugates (ADCs) represent an emerging class of targeted anticancer agents that have demonstrated impressive efficacy in numerous cancer types. In non-small cell lung cancer (NSCLC), ADCs have become a component of the treatment armamentarium for a subset of patients with metastatic disease. Emerging data suggest that some ADCs exhibit impressive activity even in central nervous system (CNS) metastases, a disease site that is difficult to treat and associated with poor prognosis. Herein, we describe and summarize the existing evidence surrounding ADCs in NSCLC with a focus on CNS activity.
抗体药物偶联物（ADCs）是一类新兴的靶向抗癌药物，在多种癌症类型中显示出了令人瞩目的疗效。在非小细胞肺癌（NSCLC）中，ADC 已成为转移性疾病患者治疗手段的一部分。新出现的数据表明，一些 ADC 即使在中枢神经系统（CNS）转移中也具有显著的活性，CNS 是一个难以治疗且预后不良的疾病部位。在此，我们描述并总结了 ADC 在 NSCLC 中的现有证据，重点关注 CNS 活性。
